Susan Bal

1.5k total citations
80 papers, 691 citations indexed

About

Susan Bal is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, Susan Bal has authored 80 papers receiving a total of 691 indexed citations (citations by other indexed papers that have themselves been cited), including 57 papers in Hematology, 40 papers in Oncology and 38 papers in Molecular Biology. Recurrent topics in Susan Bal's work include Multiple Myeloma Research and Treatments (56 papers), Protein Degradation and Inhibitors (25 papers) and CAR-T cell therapy research (15 papers). Susan Bal is often cited by papers focused on Multiple Myeloma Research and Treatments (56 papers), Protein Degradation and Inhibitors (25 papers) and CAR-T cell therapy research (15 papers). Susan Bal collaborates with scholars based in United States, Greece and Spain. Susan Bal's co-authors include Luciano J. Costa, Kelly Godby, Smith Giri, Natalie S. Callander, Anita D’Souza, Robert F. Cornell, Parameswaran Hari, Timothy M. Schmidt, Saurabh Chhabra and Rebecca Silbermann and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Blood.

In The Last Decade

Susan Bal

68 papers receiving 683 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Susan Bal United States	13	503	410	402	83	68	80	691
Shebli Atrash United States	13	521 1.0×	403 1.0×	454 1.1×	114 1.4×	73 1.1×	119	752
Naresh Bumma United States	10	226 0.4×	290 0.7×	266 0.7×	102 1.2×	79 1.2×	70	557
Silvia Buttignol Italy	5	657 1.3×	301 0.7×	392 1.0×	107 1.3×	70 1.0×	8	716
Sosana Delimpasi Greece	12	509 1.0×	399 1.0×	364 0.9×	102 1.2×	36 0.5×	61	649
Raya Mawad United States	13	264 0.5×	127 0.3×	214 0.5×	39 0.5×	88 1.3×	38	459
Rama Al Hamed France	9	308 0.6×	236 0.6×	223 0.6×	56 0.7×	21 0.3×	11	487
Verena Sagaster Austria	8	354 0.7×	297 0.7×	136 0.3×	114 1.4×	17 0.3×	17	498
Susana Vives Spain	10	533 1.1×	272 0.7×	209 0.5×	152 1.8×	12 0.2×	37	791
Ryan J. Mattison United States	12	273 0.5×	238 0.6×	111 0.3×	159 1.9×	21 0.3×	58	518
Paulo Lúcio Portugal	13	469 0.9×	255 0.6×	160 0.4×	181 2.2×	33 0.5×	30	854

Countries citing papers authored by Susan Bal

Since Specialization

Citations

This map shows the geographic impact of Susan Bal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Susan Bal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Susan Bal more than expected).

Fields of papers citing papers by Susan Bal

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Susan Bal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Susan Bal. The network helps show where Susan Bal may publish in the future.

Co-authorship network of co-authors of Susan Bal

This figure shows the co-authorship network connecting the top 25 collaborators of Susan Bal. A scholar is included among the top collaborators of Susan Bal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Susan Bal. Susan Bal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Chari, Ajai, Susan Bal, Sikander Ailawadhi, et al.. (2025). Expert Perspectives on Current Challenges and Emerging Approaches for Multiple Myeloma: Narrative Review of an Inaugural Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma. Clinical Lymphoma Myeloma & Leukemia. 25(9). 635–645.

Costa, Luciano J., et al.. (2024). P-036 BCMA after GPRC5D: Efficacy of BCMA-Directed Therapy on Patients with Relapsed/Refractory Multiple Myeloma (RRMM) Progressing After GPRC5D-Directed Therapy. Clinical Lymphoma Myeloma & Leukemia. 24. S61–S62.

Costa, Luciano J., Eva Medvedova, Binod Dhakal, et al.. (2024). Implications of MRD Progression in Newly Diagnosed Multiple Myeloma (NDMM) Treated with Quadruplet Therapy and Autologous Stem Cell Transplantation. Blood. 144(Supplement 1). 363–363. 1 indexed citations

Rangarajan, Sunil, Susan Bal, Kelly Godby, et al.. (2024). Evaluating concordance between International Myeloma Working Group (IMWG) frailty score and simplified frailty scale among older adults with multiple myeloma. Journal of Geriatric Oncology. 15(8). 102051–102051. 3 indexed citations

Janakiram, Murali, Carlyn Tan, Rakesh Popat, et al.. (2024). Real World Evidence of Outcomes of Patients Treated with Talquetamab in a Heavily Pretreated Population with Multiple Myeloma with High Exposure to Prior BCMA Therapies- a Report from the IMWG Consortium. Blood. 144(Supplement 1). 3368–3368.

Bal, Susan, Myo Htut, Jesús G. Berdeja, et al.. (2024). BMS-986393, a G Protein-Coupled Receptor Class C Group 5 Member D (GPRC5D)-Targeted CAR T Cell Therapy, in Patients (pts) with Relapsed/Refractory (RR) Multiple Myeloma (MM) and 1-3 Prior Regimens: Updated Phase 1 Safety and Efficacy Results. Blood. 144(Supplement 1). 2069–2069. 2 indexed citations

Bal, Susan & Luciano J. Costa. (2023). Bridging treatment prior to chimeric antigen receptor T‐cell therapy in multiple myeloma. British Journal of Haematology. 204(2). 449–454. 2 indexed citations

Silbermann, Rebecca, Timothy M. Schmidt, Susan Bal, et al.. (2023). Humoral immune reconstitution following therapy with daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara‐KRd), autologous hematopoietic cell transplantation, and measurable residual disease‐response‐adapted treatment cessation. SHILAP Revista de lepidopterología. 4(3). 775–778. 2 indexed citations

Bal, Susan, et al.. (2023). Outcomes of Patients with Newly Diagnosed Multiple Myeloma Experiencing Treatment Failure after Upfront Quadruplet Therapy and Autologous Stem Cell Transplantationgayathri Ravi 1, Susan Bal 1, Kelly Godby 1, Smith Giri 1, Clare Ubersax 1, Abigail Tucker 1, Luciano J Costa 1. Blood. 142(Supplement 1). 1989–1989.

10.

Bal, Susan, Kelly Godby, Smith Giri, et al.. (2023). Bendamustine Lymphodepletion (LD) Prior to Idecabtagene Vicleucel (Ide-cel) Is Associated with Inferior Outcomes in Relapsed Refractory Multiple Myeloma (RRMM). Blood. 142(Supplement 1). 6920–6920. 1 indexed citations

11.

Dhakal, Binod, Meera Mohan, Katie Palen, et al.. (2023). Dual Targeting of Slamf-7 and CD38 in Mulitple Myeloma (MM): A Phase II Study of Isatuximab, Elotuzumab, Pomalidomide and Dexamethasone (Isa-EloPD) in Relapsed and/or Refractory MM (RRMM). Blood. 142(Supplement 1). 3379–3379. 1 indexed citations

12.

Bal, Susan, et al.. (2022). Disparities in clinical trial participation among older adults with multiple myeloma in the United States. Journal of Geriatric Oncology. 13(8). 1241–1243. 2 indexed citations

13.

Chhabra, Saurabh, Rebecca Silbermann, Bhagirathbhai Dholaria, et al.. (2021). Outcomes of Hematopoietic Progenitor Cells Mobilization and Collection Following Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone Induction in Newly Diagnosed Multiple Myeloma. Transplantation and Cellular Therapy. 27(3). S70–S70.

14.

Costa, Luciano J., Saurabh Chhabra, Eva Medvedova, et al.. (2021). Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma. Journal of Clinical Oncology. 40(25). 2901–2912. 146 indexed citations

15.

Giri, Smith, Sumit Dahal, Susan Bal, et al.. (2021). Pre-treatment neutrophil to lymphocyte ratio as a biomarker of frailty and predictor of survival among older adults with multiple myeloma. Journal of Geriatric Oncology. 13(4). 486–492. 14 indexed citations

16.

Bal, Susan & Heather Landau. (2020). Solid Organ Transplantation. Hematology/Oncology Clinics of North America. 34(6). 1161–1175. 3 indexed citations

17.

Bal, Susan, Luciano J. Costa, Craig S. Sauter, Carlos Litovich, & Mehdi Hamadani. (2020). Outcomes of Autologous Hematopoietic Cell Transplantation in Diffuse Large B Cell Lymphoma Refractory to Firstline Chemoimmunotherapy. Transplantation and Cellular Therapy. 27(1). 55.e1–55.e7. 8 indexed citations

18.

Lesokhin, Alexander M., Susan Bal, & Ashraf Badros. (2019). Lessons Learned from Checkpoint Blockade Targeting PD-1 in Multiple Myeloma. Cancer Immunology Research. 7(8). 1224–1229. 30 indexed citations

19.

Bal, Susan, et al.. (2006). Incidental Detection of Mediastinal Thymoma during Tc-99m Tetrofosmin Myocardial Perfusion Imaging. Indian Journal of Nuclear Medicine. 21(2). 41. 2 indexed citations

20.

Bal, Susan, et al.. (1990). A case of follicular small cleaved cell lymphoma with t(14;18) and t(8;11). Cancer Genetics and Cytogenetics. 48(2). 199–201. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact